This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
IDAC Theranostics, Inc.
Drug Names(s): IT 1208, IT-1208
Description: IT1208 is a humanized anti-CD4 antibody with an enhanced antibody-dependent-cellularcytotoxicity (ADCC) activity using Potelligent technology from Kyowa Hakko Kirin. IT1208 transiently depletes CD4+ T cells and removes an immunosuppressive environment, leading to activation of antitumor immunity mediated mainly by CD8+ T cells.
IDAC and Ono
In May 2016, Ono Pharmaceutical announced that it entered into an option agreement with IDAC Theranostics under which ONO is granted a right for exclusive evaluation and license negotiation on IT1208, a humanized anti-CD4 antibody being developed by IDAC.
Partners: Ono Pharmaceutical Company, Ltd.
Additional information available to subscribers only: